New licensing deal signed to R&D innovative assays for infectious diseases

Hannah Blake

pharmaphorum

Oxford Immunotec, a medical diagnostic company developing tests in the fields of infectious and immunological disease, is to collaborate with Lophius Biosciences to develop novel T-cell based diagnostic test systems.

Lophius Biosciences is a leader in this field, and therefore as part of this agreement, Oxford Immunotec will be able to develop and commercialize novel T-cell based assays using Lophius’ proprietary UREA technology in certain territories.

In exchange, Lophius Biosciences will be able to develop and commercialize novel T-cell based assays under a license to Oxford Immunotec’s proprietary T-SPOT® technology.

 “We believe that Lophius’ UREA technology has distinct advantages over conventional methods of designing and producing antigens for T-cell based diagnostic test systems. We are looking forward to combining Lophius’ technology with our own, to develop and launch innovative new assays for infectious and immunological disease”.

Dr. Peter Wrighton-Smith, Chief Executive Officer, Oxford Immunotec.

Financial terms were not disclosed.

pharmaphorum-google-plus

Related news:

Oxford Immunotec and Lophius Biosciences announce new collaboration (Zenopa)

Reference links:

Oxford Immunotec press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.